Aspirin for cardioprotection and strategies to improve patient adherence

Postgraduate Medicine

Volumn 126, Issue 1, 2014, Pages 18-28

  Duffy, Danielle ^a   Kelly, Erik ^a   Trang, Amanda ^b   Whellan, David ^a   Mills, Geoffrey ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Adherence; Aspirin; Cardiovascular disease (CVD); Gastrointestinal; Safety

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ESOMEPRAZOLE; FAMOTIDINE; LANSOPRAZOLE; MISOPROSTOL; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR;

ACUTE CORONARY SYNDROME; ARTICLE; BARRETT ESOPHAGUS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CLOSTRIDIUM DIFFICILE INFECTION; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DIGESTIVE SYSTEM INJURY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; DYSPLASIA; ENDOSCOPIC SURGERY; EPIGASTRIC PAIN; GASTROESOPHAGEAL REFLUX; HEART INFARCTION; HEART PROTECTION; HEARTBURN; HUMAN; LOW DRUG DOSE; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; AGE; COMORBIDITY; HEALTH BEHAVIOR; MEDICATION COMPLIANCE; MENTAL HEALTH; PATIENT EDUCATION; PSYCHOLOGICAL ASPECT; REMINDER SYSTEM; REVIEW; SEX DIFFERENCE; SOCIAL SUPPORT; SOCIOECONOMICS;

AGE FACTORS; ASPIRIN; CARDIOVASCULAR DISEASES; COMORBIDITY; HEALTH BEHAVIOR; HUMANS; MEDICATION ADHERENCE; MENTAL HEALTH; PATIENT EDUCATION AS TOPIC; PLATELET AGGREGATION INHIBITORS; REMINDER SYSTEMS; SEX FACTORS; SOCIAL SUPPORT; SOCIOECONOMIC FACTORS;

EID: 84897019563     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.01.2721     Document Type: Article

References (89)

1. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics. Heart disease and stroke statistics—2013 update: a report from the American Heart Association [published corrections appear in Circulation. 2013;127(23):e841]. Circulation. 2013;127(1):e6–e245.
2. Laslett LJ, Alagona P Jr, Clark BA 3rd, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol. 2012;60(25 Suppl):S1–S49.
3. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013]. Circulation. 2013.
4. Smith SC Jr, Benjamin EJ, Bonow RO, et al; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–2473.
5. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. May 30 2009;373(9678):1849–1860.
6. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(6):396–404.
7. Herlitz J, Toth PP, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs. 2010;10(2):125–141.
8. Kolber MR, Korownyk C. An aspirin a day? Aspirin use across a spectrum of risk: cardiovascular disease, cancers and bleeds [published online ahead of print November 11, 2013]. Expert Opin Pharmacother. 2013.
9. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Longterm adherence with cardiovascular drug regimens. Am Heart J. 2006; 151(1):185–191.
10. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27(22):2667–2674.
11. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497.
12. Riegel B, Moser DK, Anker SD, et al; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Nutrition, Physical Activity, and Metaboloism; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research. State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation. 2009;120(12):1141–1163.
13. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074–1090; discussion 1073.
14. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003;145(3):438–444.
15. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidencebased therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004;117(2):73–81.
16. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166(17):1842–1847.
17. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203–212.
18. Kumbhani DJ, Steg PG, Cannon CP, et al; REduction of Atherothrombosis for Continued HealthRegistry Investigators. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med. 2013;126(8):693–700.
19. Bi Y, Gao R, Patel A, et al; CPACS Investigators. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study. Am Heart J. 2009;157(3):509–516.
20. Kronish IM, Rieckmann N, Burg MM, Alcantara C, Davidson KW. The Psychosocial Context Impacts Medication Adherence After Acute Coronary Syndrome [published online ahead of print October 26, 2013]. Ann Behav Med. 2013.
21. Moberg C, Naesdal J, Svedberg LE, Duchateau D, Harte N. Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic Acid: a quantitative study in patients with cardiovascular risk. Patient. 2011;4(2):103–113.
22. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882–887.
23. Lehmann A, Aslani P, Ahmed R, et al. Assessing medication adherence: options to consider [published online ahead of print October 29, 2013]. Int J Clin Pharm. 2013.
24. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–1310.
25. Gengiah TN, Moosa A, Naidoo A, Mansoor LE. Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection [published online ahead of print October 16, 2013]. Int J Clin Pharm. 2013.
26. Casebeer L, Huber C, Bennett N, et al. Improving the physician-patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract. 2009;10:48. doi: 10.1186/1471-2296-10-48.
27. Arora S, Peters AL, Burner E, Lam CN, Menchine M. Trial to Examine Text Message-Based mHealth in Emergency Department Patients With Diabetes (TExT-MED): A Randomized Controlled Trial. Ann Emerg Med. 2013;pii: S0196-0644(13)0148-8.
28. George MG, Tong X, Sonnenfeld N, Hong Y; Centers for Disease Control and Prevention (CDC). Recommended use of aspirin and other antiplatelet medications among adults—National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, United States, 2005–2008. MMWR Morb Mortal Wkly Rep. 2012;61(Suppl):11–18.
29. Arnold SV, Spertus JA, Masoudi FA, et al. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. J Am Coll Cardiol. 2013;62(19):1791–1801.
30. Mehta RH, Montoye CK, Gallogly M, et al; GAP Steering Committee of the American Colege of Cardiology. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002;287(10):1269–1276.
31. LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164(2):203–209.
32. Eagle KA, Montoye CK, Riba AL, et al; American College of Cardiology’s Guidelines Applied in Practice (GAP) {rojects in Michigan; American College of Cardiology Foundation (Bethesda, Maryland) Guidelines Applied in Practice Steering Committee. Guideline-based standardized care is associated with substantially lower mortality in medicare patients with acute myocardial infarction: the American College of Cardiology’s Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol. 2005;46(7):1242–1248.
33. Hassan Y, Kassab Y, Abd Aziz N, Akram H, Ismail O. The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge. J Clin Pharm Ther. 2013;38(2):97–100.
34. McNamara KP, O’Reilly SL, Dunbar JA, et al. A pilot study evaluating multiple risk factor interventions by community pharmacists to prevent cardiovascular disease: the PAART CVD pilot project. Ann Pharmacother. 2012;46(2):183–191.
35. Albert NM, Fonarow GC, Yancy CW, et al. Outpatient cardiology practices with advanced practice nurses and physician assistants provide similar delivery of recommended therapies (findings from IMPROVE HF). Am J Cardiol. 2010;105(12):1773–1779.
36. Thom S, Poulter N, Field J, et al; UMPIRE Collaborative Group. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310(9):918–929.
37. Orloff DG. Fixed combination drugs for cardiovascular disease risk reduction: regulatory approach. Am J Cardiol. 2005;96(9 A):28K–33K; discussion 34K–35K.
38. Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 1995;14(1):88–90.
39. Rieckmann N, Kronish IM, Haas D, et al. Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes. Am Heart J. 2006;152(5):922–927.
40. Glynn RJ, Buring JE, Manson JE, LaMotte F, Hennekens CH. Adherence to aspirin in the prevention of myocardial infarction. The Physicians’ Health Study. Arch Intern Med. 1994;154(23):2649–2657.
41. Toth L, Muszbek L, Komaromi I. Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM/MM calculations. J Mol Graph Model. 2013;40:99–109.
42. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999; 117(1):17–25.
43. Park K, Bavry AA. Aspirin: its risks, benefits, and optimal use in preventing cardiovascular events [published corrections appear in Cleve Clin J Med. 2013;80(7)435]. Cleve Clin J Med. 2013;80(5):318–326.
44. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329–1339.
45. Laheij RJ, Jansen JB, Verbeek AL, Verheugt FW. Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease. Aliment Pharmacol Ther. 2001;15(7):1055–1059.
46. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23(1):163–173.
47. Cea Soriano L, Rodriguez LA. Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes. Front Pharmacol. 2010;1:126. doi: 10.3389/fphar.2010.0012.
48. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2002;16(4):779–786.
49. Ng W, Wong WM, Chen WH, et al. Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. World J Gastroenterol. 2006;12(18):2923–2927.
50. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther. 2002;16(11):1945–1953.
51. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343(12):834–839.
52. de Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001;1:1.
53. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al; Asociacion Espanola de Gastroenterologia. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional nonaspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55(12):1731–1738.
54. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310(6983):827–830.
55. Udd M, Miettinen P, Palmu A, et al. Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: a case-control study. Scand J Gastroenterol. 2007;42(12):1395–1403.
56. Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–738.
57. Valkhoff VE, Sturkenboom MC, Kuipers EJ. Risk factors for gastrointestinal bleeding associated with low-dose aspirin. Best Pract Res Clin Gastroenterol. 2012;26(2):125–140.
58. Sappok T, Faulstich A, Stuckert E, Kruck H, Marx P, Koennecke HC. Compliance with secondary prevention of ischemic stroke: a prospective evaluation. Stroke. 2001;32(8):1884–1889.
59. De Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A; Dutch TIA trial and SPIRIT study groups. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol. 2005;252(11):1316–1321.
60. Komiya T, Kudo M, Urabe T, Mizuno Y. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing. Stroke. 1994;25(12):2337–2342.
61. Wang Y, Wu D, Ma R, Wang C, Zhao W. A survey on adherence to secondary ischemic stroke prevention. Neurol Res. 2006;28(1):16–20.
62. Newby LK, Bhapkar MV, White HD, et al; SYMPHONY and 2nd SYMPHONY investigators. Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. J Thromb Thrombolysis. 2003;16(3):119–128.
63. Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005;62(8):1217–1220.
64. Pratt S, Thompson VJ, Elkin EP, Næsdal J, Sorstadius E. The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs. 2010;10(5):281–288.
65. Bower AB, Grau SL, Taylor VA. Over-the-counter vs. prescription medications: are consumer perceptions of the consequences of drug instruction non-compliance different? International Journal of Consumer Studies. 2013;37(2)228–233.
66. Carney RM, Freedland KE, Eisen SA, Rich MW, Skala JA, Jaffe AS. Adherence to a prophylactic medication regimen in patients with symptomatic versus asymptomatic ischemic heart disease. Behav Med. 1998;24(1):35–39.
67. Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med. 2013;126(4):e7–e327.
68. Quilici J, Fugon L, Beguin S, et al. Effect of motivational mobile phone short message service on aspirin adherence after coronary stenting for acute coronary syndrome. Int J Cardiol. 2013;168(1):568–569.
69. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with entericcoated or buffered product. Lancet. 1996;348(9039):1413–1416.
70. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103(10):2465–2473.
71. Sylvester KW, Cheng JW, Mehra MR. Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events. Vasc Health Risk Manag. 2013;9:245–254.
72. Martin Merino E, Johansson S, Nagy P, Garcia Rodriguez LA. Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United kingdom primary care. Am J Cardiol. 2013;112(8):1075–1082.
73. Hedberg J, Sundstrom J, Thuresson M, Aarskog P, Oldgren J, Bodegard J. Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding— a cohort study of the effects of proton pump inhibitor use patterns. J Intern Med. 2013;274(4):371–380.
74. Mosca L, Benjamin EJ, Berra K, et al; American Heart Association. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57(12):1404–1423.
75. Vandvik PO, Lincoff AM, Gore JM, et al; American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e637S–e6368S.
76. Goldstein LB, Bushnell CD, Adams RJ, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research; Council on Peripheral Vascular Disease; Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [corrections published in Stroke. 2011;42(2):e26]. Stroke. 2011;42(2):517–584.
77. O’Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–e425.
78. Writing Committee Members, Jneid H, Anderson JL, Wright RS, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-STelevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2012;126(7):875–910.
79. Furie KL, Kasner SE, Adams RJ, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Clinical Cardiologu; Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(1):227–276.
80. You JJ, Singer DE, Howard PA, et al; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e531S–e575S.
81. Rooke TW, Hirsch AT, Misra S, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Intervenitonal Radiology; Society for Vascular Medicine; Society for Vascular Surgery. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guidelines): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58(19):2020–2045.
82. Brott TG, Halperin JL, Abbara S, et al; Amican College of Cardiology; American Stroke Association; American Association of Neurological Surgeons; American College of Radiology; Society of NeuroInterventional Surgery; Society for Vascular Medicine; Society for Vascular Surgery. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/ SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Circulation. 2011;124(4):e54–e130.
83. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH; American College of Chest Physicians. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e576S–e600S.
84. Newburger JW, Takahashi M, Gerber MA, et al; Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease; Council on Cardiovascular Disease in the Young; American Heart Association; American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110(17):2747–2771.
85. Sud A, Kline-Rogers EM, Eagle KA, et al. Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother. 2005; 39(11):1792–1797.
86. Wald DS, Morton G, Walker K, Iosson N, Curzen NP. Long-term continuation on cardiovascular drug treatment in patients with coronary heart disease. Ann Pharmacother. 2007;41(10):1644–1647.
87. Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. The PACE pilot study: 12-month results and implications for future primary prevention trials in the elderly. (Prevention with low-dose Aspirin of Cardiovascular disease in the Elderly). J Am Geriatr Soc. 1994;42(6):643–647.
88. Waeber B, Leonetti G, Kolloch R, McInnes GT. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens. 1999;17(7):1041–1045.
89. Frishman WH. Enhancing medical adherence [published corrections appear in Am J Med. 2013;126(6):e25]. Am J Med. 2012;125(9):841–842.